297 related articles for article (PubMed ID: 18342708)
1. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
4. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
5. How to manage hypersensitivity reactions to biological agents?
Barbaud A; Granel F; Waton J; Poreaux C
Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
[TBL] [Abstract][Full Text] [Related]
6. [Cutaneous side effects of EGF receptor inhibitors].
Nassar D; Soutou B; Aractingi S
Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
[TBL] [Abstract][Full Text] [Related]
7. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
8. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects of antiangiogenic agents].
Robert C
Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
11. [Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Sibaud V; Robert C
Ann Dermatol Venereol; 2013 Apr; 140(4):266-73. PubMed ID: 23567227
[TBL] [Abstract][Full Text] [Related]
12. [Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Pérez López G; Carrasco De La Fuente M; Menacho Román M; González Albarrán O; Cano Megías M
Endocrinol Nutr; 2011 Feb; 58(2):94-6. PubMed ID: 21333617
[No Abstract] [Full Text] [Related]
13. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
14. [Dermatologic side effects induced by new angiogenesis inhibitors].
Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
[TBL] [Abstract][Full Text] [Related]
15. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib: muscle wasting.
Prescrire Int; 2011 Dec; 20(122):296-7. PubMed ID: 22216546
[TBL] [Abstract][Full Text] [Related]
17. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
18. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
Lacouture ME; Melosky BL
Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]